Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Area of Science:

• Hematology
• Oncology
• Clinical Guidelines

Background:

• Acute Lymphoblastic Leukemia (ALL) presents diverse subtypes requiring tailored treatment.
• Risk stratification is crucial for effective, individualized therapy in ALL patients.
• Management of Philadelphia chromosome-positive (Ph+) ALL necessitates specific therapeutic approaches.

Purpose of the Study:

• To provide updated NCCN Guidelines for the management of ALL.
• To detail treatment strategies for Ph-positive and Ph-negative ALL in adolescents and young adults.
• To address supportive care and relapsed ALL management.

Main Methods:

• Guideline development based on expert consensus and evidence review.
• Classification of ALL subtypes using immunophenotype and molecular markers.
• Risk stratification for guiding therapy selection in ALL.

Main Results:

• Comprehensive strategies for Ph-positive and Ph-negative ALL in young adults.
• Recommendations for supportive care in ALL patients.
• Guidance on managing relapsed ALL settings.

Conclusions:

• NCCN recommends specialized cancer centers for ALL management due to treatment complexity.
• Risk-adapted therapy is central to current ALL treatment protocols.
• Updated guidelines support optimal care for diverse ALL patient populations.